Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Author(s) -
Katelyn A Pastick,
Elizabeth C Okafor,
Fan Wang,
Sarah M Lofgren,
Caleb P Skipper,
Melanie R. Nicol,
Matthew F Pullen,
Radha Rajasingham,
Emily G. McDonald,
Todd C. Lee,
Ilan S. Schwartz,
Lauren E. Kelly,
Sylvain Lother,
Natàlia Casamitjana,
Emili Letang,
Mahsa Abassi,
David R. Boulware
Publication year - 2020
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofaa130
Subject(s) - hydroxychloroquine , chloroquine , medicine , covid-19 , coronavirus , clinical trial , intensive care medicine , virology , disease , pathology , infectious disease (medical specialty) , outbreak , malaria
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom